Vor Biopharma
Open
$14.43
Prev. Close
$14.42
High
$14.44
Low
$14.37
Market Snapshot
$701.45M
-0.8
-1.70
76
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
Recently from Cashu
Vor Biopharma: Pioneering Personalized Medicine Amid Energy Transition Opportunities
Vor Biopharma and the Future of Energy Transition: A Strategic Opportunity Vor Biopharma, a company focused on pioneering therapies in personalized medicine, finds itself at a unique intersection of h…
Vor Biopharma: Leading Biopharmaceutical Innovation Amidst the Energy Transition Movement
Vor Biopharma and the Energy Transition: A New Paradigm in Biopharmaceuticals Vor Biopharma, a trailblazer in the biopharmaceutical industry, stands at the intersection of innovation and sustainabilit…
Vor Biopharma: Leading Innovation in Targeted Therapies and Sustainable Biopharmaceutical Solutions
Vor Biopharma: Pioneering Innovations in Biopharmaceuticals Vor Biopharma stands at the forefront of advancements in the biopharmaceutical sector, focusing on the development of targeted therapies tha…
Vor Biopharma Explores Luxury: Launch of Ramón Allones Absolutos Edición Limitada 2024
Elevating Luxury: The Launch of Ramón Allones Absolutos Edición Limitada 2024 In a celebration of craftsmanship and luxury, Habanos, S.A. and its exclusive distributor Intertabak AG recently unveiled…